Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

Metabolic dysfunction-associated steatotic disease (MASLD) is a chronic liver condition, characterised by the accumulation of fat in liver, association with metabolic disorder. It lobular inflammation and hepatocyte enlargement, both which contribute to development steatosis—an fatty acids liver. This condition may arise due either impaired acid breakdown or increased delivery lipids [1]. The progression be attributed leakage intestinal bacteria [2]. Affecting about 25% world's population, MASLD growing global concern Treatment strategies for include lifestyle modification, weight loss several medications including PPAR agonists, SGLT2 inhibitors, GLP-1 receptor ASK1 modulation certain microbial communities lubiprostone [3, 4]. A recent study El-Kassas et al. highlighted beneficial role patients MASLD. trial demonstrates that reduces content used as treatment leaky gut those elevated ALT levels [5]. Lubiprostone acts chloride channel-2 agonist accelerates recovery epithelial barrier injury. Altered bile flow affects endotoxin translocation helps mitigate this damage [6]. Another Kim observed effects it prevents bacterial leakage\ strengthens promoting colonic mucus. Its on increasing portal HDL cholesterol levels, reducing burden mitigating hepatic steatosis. In high-fat diet-induced MASLD/NAFLD, has demonstrated high efficacy emerges favourable therapeutic agent exhibiting effectiveness steatosis, enhancing profiles enzymes enforcing barrier-oriented functions intestine. benefits appear not dependent enzyme status constipation, underscores its wide potential management. However, large-scale, randomised controlled trials are needed authenticate these findings, explore long-term safety render their significant normal levels. Upcoming research should also investigate mechanisms action diverse populations so can maximise Hassan Javed: conceptualization, investigation, writing – original draft. Muhammad Umar Ahsan: draft, data curation, software, formal analysis, supervision. Saeed: curation. Qintar Taqi: IRB approval was required because no were collected article. authors declare conflicts interest. article linked al papers. To view articles, visit https://doi.org/10.1111/apt.18478 https://doi.org/10.1111/apt.70048. support findings available Pubmed at https://pubmed.ncbi.nlm.nih.gov/. These derived from following resources public domain: PubMed,

Language: Английский

---

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Language: Английский

---

Letter: Lubiprostone—A Novel Therapeutic Avenue for Gastrointestinal Complications in MASLD. Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 18, 2025

We thank Dr. Javed et al. [1] for their comments and interest in our recent study [2] on the potential role of lubiprostone metabolic dysfunction-associated steatotic liver disease (MASLD). Their discussion highlights key aspects findings provides an opportunity to further clarify broader implications report. Our randomised controlled demonstrated that significantly reduces fat content, as measured by MRI-PDFF, independent baseline enzyme levels or constipation status. These suggest could be effective across a spectrum MASLD patients, including those with normal ALT levels. This observation is particularly relevant given substantial proportion patients have enzymes, treatment strategies should not limited only biochemical abnormalities. Regarding gut permeability endotoxin translocation pathogenesis, lubiprostone's ability enhance intestinal barrier function reduce leakage has been documented preclinical models [3, 4] aligns well proposed 'gut-liver axis' hypothesis MASLD. While did specifically assess changes levels, significant reduction hepatic steatosis observed suggests modulation may contribute beneficial effects. Further studies incorporating direct measurements microbial markers would provide additional mechanistic insights. adds previous work Kessoku [5] demonstrating impact subgroup constipation. extends these showing remains even absence constipation, reinforcing its therapeutic agent wider population. As correctly noted letter, need larger, well-powered, multi-centre trials paramount. Such include diverse patient populations, moderate advanced fibrosis, long-term safety investigate whether can influence fibrosis progression, critical endpoint treatment. Mohamed El-Kassas: conceptualization, writing – original draft, review editing. Hongqun Liu: Samuel S. Lee: IRB approval was required because no data collected this article. The authors declare conflicts interest. article linked El-Kassas al papers. To view articles, visit https://doi.org/10.1111/apt.18478 https://doi.org/10.1111/apt.70035. support are available request from corresponding author. publicly due privacy ethical restrictions.

Language: Английский

---

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply

Alimentary Pharmacology & Therapeutics, Journal Year: 2025, Volume and Issue: unknown

Published: April 3, 2025

Language: Английский

---